Home › Funds › TANDEM CAPITAL MANAGEMENT CORP /ADV › ABT

TANDEM CAPITAL MANAGEMENT CORP /ADV position in ABT

ABBOTT LABORATORIES · Health Care

TANDEM CAPITAL MANAGEMENT CORP /ADV reported holding 31,168 shares of ABT (ABBOTT LABORATORIES) in its Q3 2026 13F filing — a position valued at US$3.1M, representing 1.36% of its reported portfolio and ranking #20 among its reported holdings. TANDEM CAPITAL MANAGEMENT CORP /ADV has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)31.17K sh
Reported value held$3.08M
Portfolio Weight1.36%
First reportedQ3 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How TANDEM CAPITAL MANAGEMENT CORP /ADV's ABT position evolved

TANDEM CAPITAL MANAGEMENT CORP /ADV first disclosed a stake in ABT in Q3 2023 at 33,252 shares (US$3.2M). The position peaked in Q2 2025 at 30,133 shares, worth US$4.1M. Across 13 filings, TANDEM CAPITAL MANAGEMENT CORP /ADV increased the stake 2 time(s), trimmed it 6 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 31,168 shares valued at US$3.1M — an increase of 170 shares quarter over quarter..

Quarter by quarter

QuarterSharesValueChange
Q3 2023 33.25K $3.22M New
Q4 2023 32.94K $3.63M Reduce
Q1 2024 32.98K $3.75M Hold
Q2 2024 32.15K $3.34M Reduce
Q3 2024 31.07K $3.54M Reduce
Q4 2024 30.35K $3.43M Reduce
Q1 2025 30.23K $4.01M Hold
Q2 2025 30.13K $4.10M Hold
Q3 2025 29.94K $4.01M Reduce
Q4 2025 29.94K $3.75M Hold
Q1 2026 29.34K $3.01M Reduce
Q2 2026 31.00K $2.81M Add
Q3 2026 31.17K $3.08M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ABT and 13F data

ABT (ABBOTT LABORATORIES) is a Health Care company. 21 other funds we track also report a position in ABT — the largest reported positions include Vanguard Group (US$22.00B), Charles Schwab Investment Management (US$5.41B), CHARLES SCHWAB INVESTMENT MANAGEMENT INC (US$5.41B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ABT

All ABT fund holders →

FAQ

How long has TANDEM CAPITAL MANAGEMENT CORP /ADV held ABT?

TANDEM CAPITAL MANAGEMENT CORP /ADV has disclosed ABT holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is TANDEM CAPITAL MANAGEMENT CORP /ADV's current position in ABT?

As of Q3 2026, TANDEM CAPITAL MANAGEMENT CORP /ADV holds 31.17K shares of ABT (ABBOTT LABORATORIES), valued at $3.08M, representing 1.36% of its reported portfolio and ranking #20.

Has TANDEM CAPITAL MANAGEMENT CORP /ADV been buying or selling ABT?

In the latest 13F filing (Q3 2026), TANDEM CAPITAL MANAGEMENT CORP /ADV increased its position in ABT. The position peaked in Q2 2025 at 30.13K shares.

Which other funds hold ABT?

Other major institutional holders of ABT include Vanguard Group, Charles Schwab Investment Management, CHARLES SCHWAB INVESTMENT MANAGEMENT INC, among 21 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.